Compare Charles River Laboratories Intl. Inc (CRL) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs TORM plc — how do they compare? Charles River Laboratories Intl. Inc trades at $299.21 (market cap $14.23B), while TORM plc trades at $40.22 (market cap $4.12B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3.5× TORM plc's market cap, and TORM plc pays a 11.03% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and TORM plc for 23 Days on average.
| CRL | TRMD | |
|---|---|---|
Market Cap | $14.23B | $4.12B |
Volume | 1,176,885 | 2,863,116 |
Sector | Health | Industrials |
52-Week High | $310.77 | $41.05 |
52-Week Low | $149.93 | $19.39 |
Typical Hold Time | 33 Days | 23 Days |
Enterprise Value | $17.06B | $4.83B |
Dividend Yield | — | 11.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
TRMD trades at $38.92, down 0.33% on the day, with strong technical momentum showing a bullish moving average signal despite RSI_6 indicating potential overbought conditions. Fundamentally, the company demonstrates robust profitability with 35.52% net income margin and attractive valuation metrics including a 6.59 P/E ratio. Recent earnings showed mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates.
The outlook remains positive with 100% analyst buy ratings and improving cash flow projections for 2026. Key risks include spot rate volatility in the tanker market and recent insider selling activity. The stock offers value characteristics with strong dividend potential but faces near-term headwinds from declining contracted rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
